Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AIM ImmunoTech Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards Quiver Quantitative, Inc. - Wed Dec 18, 1:56AM CST

AIM ImmunoTech Inc. notified of non-compliance with NYSE American listing standards, requires plan for compliance by January 2025.Quiver AI SummaryAIM ImmunoTech Inc. announced that it has received a notice...

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards GlobeNewswire - Tue Dec 17, 3:45PM CST

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Inc. Granted Patent for Ampligen® in Treatment of Post-COVID Fatigue Quiver Quantitative, Inc. - Thu Dec 12, 6:28PM CST

AIM ImmunoTech announces Netherlands patent granted for Ampligen® treatment of post-COVID fatigue, expanding its intellectual property portfolio.Quiver AI SummaryAIM ImmunoTech Inc. announced the granting...

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue GlobeNewswire - Thu Dec 12, 8:00AM CST

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Inc. Releases Virtual Investor Segment Featuring Dr. Charles Lapp Discussing Ampligen® and ME/CFS Research Quiver Quantitative, Inc. - Fri Dec 6, 6:26PM CST

AIM ImmunoTech released a segment featuring Dr. Charles Lapp on Ampligen®'s potential for treating Post-COVID fatigue.Quiver AI SummaryAIM ImmunoTech Inc. has released a Virtual Investor KOL Connect segment...

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment GlobeNewswire - Fri Dec 6, 8:15AM CST

AIM : 0.1900 (-0.58%)
Insider Purchase: CEO & President of $AIM (AIM) Buys 85,000 Shares Quiver Quantitative, Inc. - Thu Nov 21, 9:20PM CST

Thomas K Equels, the CEO & President of $AIM ($AIM), bought 85,000 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

AIM : 0.1900 (-0.58%)
Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares Quiver Quantitative, Inc. - Wed Nov 20, 10:08PM CST

Thomas K Equels, the CEO & President of $AIM ($AIM), bought 60,110 shares of the company on 11-20-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Inc. Announces Publication of Promising Data from Roswell Park Phase 1 Study on Ampligen® for Early-Stage Triple-Negative Breast Cancer Quiver Quantitative, Inc. - Tue Nov 19, 5:20PM CST

AIM ImmunoTech announces promising Phase 1 trial results for Ampligen® in early-stage triple-negative breast cancer.Quiver AI SummaryAIM ImmunoTech Inc. announced the publication of promising data from...

AIM : 0.1900 (-0.58%)
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer GlobeNewswire - Tue Nov 19, 7:00AM CST

AIM : 0.1900 (-0.58%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot